Best Clinical Trial Site Networks (2026)

Who this guide is for

This guide is for clinical operations leads, startup and enrolment specialists, and biotech founders choosing how to source sites for a trial. It is for teams weighing a site network against the traditional route of selecting independent sites one by one, for sponsors reviewing the site component of a CRO proposal, and for groups designing decentralised or hybrid studies that depend on community-based sites reaching patients where they are.

If you are looking for clinical trial site networks, treat the vendor cards and table on this page as a starting point, not a verdict. They show which networks and site management organisations are listed and how each profile describes its focus; they cannot tell you how a network performs on a protocol like yours, in your indication, in your regions. Use the evaluation criteria below to structure the search and the questions to ask before any agreement is signed.

What a site network does — and when you need one

A site network is a group of clinical sites or investigators operating under shared ownership, branding or coordination. Some networks own their clinics outright; others federate independent practices under common quality, training and technology standards. A site management organisation, closely related, provides management services to sites without owning them. What both sell, ultimately, is access: to sites, to staff, to patient populations, and to a coordination layer that lets a sponsor reach all of it through one relationship instead of dozens.

The traditional alternative is sponsor- or CRO-led site selection, where each site is contracted, trained and managed individually. That route keeps full control but is slow, and enrolment depends on how well each site was chosen. A network trades some of that control for speed and reach: pre-qualified sites that can activate together, staff who have worked as a team before, and centralised contracting, budgeting and reporting.

Typical trigger points are a competitive enrolment race, a protocol that needs a specific or hard-to-reach population, a sponsor running several studies and tired of repeating site selection, a decentralised design that needs community sites rather than large hospital campuses, or a study whose independent sites have under-delivered and needs a reset.

Networks themselves come in recognisable types, and the type shapes what you are buying. Owned-clinic networks control their sites directly, which gives consistent processes and staffing but concentrates activity where the network happens to operate. Federated networks coordinate independent practices under shared standards, which buys reach and variety at the cost of more heterogeneous execution. Networks built around a specific patient community, such as a therapeutic-area registry or a group of primary care practices, trade breadth for depth of access to precisely the population a protocol needs. Hybrid models mix these, and large groups may operate several of these structures at once.

Site networks in decentralised and hybrid designs

Decentralised and hybrid protocols change what a site is. When visits happen at home, at a local clinic or through telehealth, the network's role shifts from hosting visits to anchoring them: providing the physical touchpoints a protocol still needs, the local staff who build trust with participants, and the logistics of nursing visits, sample collection and device delivery across a wide area. Networks with community or primary-care roots are often better positioned for this than hospital-centric groups, precisely because their sites already sit inside patients' daily lives.

Ask a prospective network what decentralised components it has actually run, not just what it is willing to attempt: home nursing coverage and its geography, telehealth platforms and how visits are documented, shipping lanes for investigational product and samples, and how local regulations across its footprint treat remote and home-based activities. The answers separate networks that have built this muscle from those renting it for your study specifically.

Hybrid designs also blur oversight. When some visits happen outside any site, accountability for those activities needs a named owner in the agreement. Ask who is responsible when a home visit goes wrong, how deviations that happen outside site walls are documented, and how the network keeps sponsor visibility into activities it does not directly host.

How to evaluate a site network vendor

Coverage, therapeutic fit and genuine readiness

Ask which indications the network's sites have actively run, with what recent enrolment, rather than what is theoretically within scope. Geographic coverage should be mapped against your target population, and site lists should be current: networks change, sites close, and a list padded with dormant locations will disappoint at startup. Ask how many of the sites proposed for your study are startup-ready today, with current regulatory documentation and trained staff.

Site quality and performance history

Ask for historical performance at the level you will actually experience: enrolment against plan, screen failure rates, protocol deviation rates, query turnaround and audit or inspection findings across the network's sites. A serious network tracks this and can discuss it openly. Where a network resists sharing performance history, treat that as due-diligence data in itself.

Activation speed and contracting model

One of the main reasons sponsors choose networks is startup speed. Pre-qualified sites, template agreements and centralised budgeting can compress site selection to activation dramatically. Ask for recent startup timelines on studies resembling yours, how parallel the activation steps really are, what the fair market value process looks like, and what happens when one site in the network is not ready. Get commitments in the agreement, not the pitch.

Patient access, finding and diversity

Ask what patient-finding infrastructure the network brings: databases, community relationships, outreach channels, telehealth and home nursing capabilities for decentralised designs. Where the protocol needs broad population representation, ask how sites are chosen for reach, how under-represented groups are genuinely served rather than nominally included, and what retention support continues after enrolment. Enrolment is only half the story; keeping participants in the study is the other half.

Dig into how the network knows its populations. A network that can describe its catchments, referral patterns and previous success reaching the groups your protocol needs is working from evidence; one that gestures at large patient databases without detail is working from hope. Ask what happened on studies where enrolment lagged, and what the network changed afterwards. That answer reveals more about operational maturity than any capability slide.

Quality systems, training and oversight

Ask how the network standardises quality across its sites: shared standard operating procedures, central training records, internal audit programmes and how findings are closed out. For federated models, ask what happens when a member site fails an audit or underperforms persistently, and whether the network can remove a site mid-study. Consistent training on your protocol matters as much as baseline quality: ask who delivers it, how competency is verified before a site enrolls its first participant, and how new staff are brought up to standard during a running study.

Data, technology and oversight alignment

Ask what reporting the network provides as standard and in which formats, how its systems connect to your electronic data capture and study dashboards, and who at the network owns data quality issues when they surface. If the network supplies pre-screening data from its own records, ask how privacy rules are respected and how that data is documented. Consistent oversight across a network is easier than across scattered independent sites, but only if the network's own standards are documented and audited.

Commercial model and capacity

Networks price in different ways: per-visit study budgets, per-patient payments, access fees, and hybrid structures with performance components. Model the total cost of delivery across a realistic enrolment scenario, including pass-through costs, rather than comparing headline rates. Ask what capacity the network has committed to other sponsors, because a network that has sold the same sites twice will let you down at the worst moment.

Contract structure deserves the same attention as price. Ask about fair market value documentation, indirect cost handling, payment terms and how protocol amendments are priced. Where a sponsor plans several studies, ask about network-wide or portfolio agreements that simplify each future startup. And ask what happens at the end of the relationship: how records, samples and data are returned, and what obligations survive the study.

Site networks at a glance

The table below lists site networks and site management organisations whose profiles state the study phases they support, so you can compare service model, footprint and study coverage before you open individual pages. Records that do not yet list phases remain in the vendor directory.

The fields come from each vendor’s Clinical Vendor Compare profile, and blank cells mean the record is silent. Many site network records use the same standard wording for their best fit and strengths, so the table separates networks mainly by service model, footprint and phase coverage. A field reading Generalist, Global or Multi Region means the record does not narrow the areas or countries covered; it is not evidence of breadth or of site counts. Profiles summarise what a vendor publicly offers; they are not an assessment of site quality, and they cannot substitute for the performance history and reference conversations described above.

Vendor profiles

Velocity Clinical Research

Velocity Clinical Research is listed as a large site network headquartered in the United States, with a footprint its record describes as United States and global, covering Phase I to Phase IV with a generalist remit. Its record lists site access, startup speed and enrolment throughput as strengths, and notes that coverage may vary by geography and indication. Where to probe: map its proposed sites against your target population before assuming coverage.

Elligo Health Research

Elligo Health Research's record describes a technology-enabled site network with patient recruitment capability, giving sponsors access to community-based research sites with pre-identified patient populations, and an approach that draws on electronic health record data to support site selection and enrolment. It is headquartered in the United States, covers Phase I to Phase IV, and lists decentralised and hybrid trial capability. Its record notes the network is primarily US-based with limited presence outside the United States. Where to probe: ask how health record data are used under privacy rules, and how pre-identified patients convert to enrolled participants.

Accellacare

Accellacare is listed as a site network with a focus on a global clinical research network and a footprint its record describes as Europe and global, covering Phase I to Phase IV with a generalist remit. Where to probe: ask which countries and indications its sites have recently enrolled in, and how quality standards are kept consistent across countries.

Alcanza Clinical Research

Alcanza Clinical Research's record describes a site network focused on site footprint, investigator access and enrolment throughput in North America, covering Phase II to Phase IV. Its record lists site density, start-up leverage and enrolment reach as strengths. Where to probe: for a first-in-human or early Phase I study, confirm support beyond the phases listed.

AMR Alliance for Multispecialty Research and Alliance for Multispecialty Research (AMR)

Two records in the table carry the AMR name with different fields. One lists a site network with a multi-region footprint and a generalist remit across Phase I to Phase IV. The other lists a site management organisation headquartered in the United States with a North American footprint, covering Phase I to Phase IV across oncology, cardiovascular, immunology, infectious disease and neurology, with multi-specialty coverage, diverse patient populations and experienced investigators as stated strengths, and US-only coverage and a mid-size network as stated limitations. Where to probe: confirm with the organisation which entity and footprint you would contract with.

Avacare Clinical Research Network

Avacare Clinical Research Network is listed as a site network with a network model and a United States footprint, covering Phase I to Phase IV with a generalist remit. Its stated best fit is sponsors needing rapid access to ready-to-enrol sites. Where to probe: ask which of its sites are startup-ready for your indication today.

Benchmark Research

Benchmark Research's record describes a multi-region site network covering Phase I to Phase IV, aimed at sponsors wanting direct access to sites, investigators and enrolment infrastructure. Its record lists site access, patient pools and repeatable execution as strengths, and notes it may be less useful when a sponsor already has a fixed preferred site panel. Where to probe: ask how its sites would complement, rather than duplicate, sites you already use.

Catalyst Clinical Sites

Catalyst Clinical Sites is listed as a multi-region site network covering Phase I to Phase IV with a generalist remit, and a stated best fit of sponsors needing rapid access to ready-to-enrol sites. The record describes its services in general terms. Where to probe: ask for recent enrolment against plan in your indication and the current list of sites it would propose.

Cedar Health Research

Cedar Health Research's record describes a multi-region site network covering Phase I to Phase IV, aimed at sponsors wanting direct access to sites, patient pools and execution infrastructure, with site access, network reach and recruitment as stated strengths. Like Benchmark Research, its record notes it may be less useful where a sponsor already has a fixed preferred site panel. Where to probe: ask how it finds and retains participants in your target population.

Engagement and pricing models

Site network engagements usually combine several elements: study start-up fees for regulatory documents, contracting and site initiation; per-visit or per-procedure study budgets paid as participants progress; recruitment and pre-screening costs, sometimes priced separately; pass-through costs such as investigational product handling, local laboratory work and participant reimbursement; and, for some networks, access or retainer fees for preferred or portfolio relationships. Performance components tied to enrolment milestones are increasingly common.

The main cost drivers are the number of sites, visit and procedure intensity, the difficulty of the target population, and how much recruitment work the network takes on. Agree in advance how screen failures, protocol amendments, under-enrolling sites and early termination will be paid, and compare offers on the total cost of a realistic enrolment scenario rather than on headline per-participant rates.

Questions to put in your RFP

• Which of the sites you propose are startup-ready today, with current documentation and trained staff?
• What enrolment against plan have your sites delivered recently in this indication?
• What did startup-to-activation look like on your last comparable study?
• How do you select sites for patient reach, and what community relationships support that?
• What retention support continues after a participant is enrolled?
• What reporting do you provide as standard, and in which formats?
• How do your systems connect to our electronic data capture and dashboards?
• What capacity at these sites is already committed to other sponsors?
• What happens commercially and operationally when a study under-enrols?
• How are audit and inspection findings across your sites tracked and resolved?

Due-diligence red flags

• Site lists that include dormant or recently departed locations.
• Performance history that cannot be shared, or only in aggregate with no detail.
• Startup speed promised in the pitch but absent from the agreement.
• Diversity described as a value rather than a set of practices with evidence.
• The same capacity quietly sold to several sponsors.
• Reporting that arrives late, in inconsistent formats, or not at all during references.
• No clear owner for data quality issues once the study is running.
• Pass-through costs that surface only after the budget is signed.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter for site networks to see every listed provider. Open profiles to check model and footprint, then place a few side by side on the compare page to separate owned networks from federated site management organisations. Networks often carry a technology layer, so also read the guide to eClinical and EDC vendors; if enrolment risk is the core worry for a late-phase programme, see the guide to biometrics partners for late-phase trials. When your requirements are clear, use the sponsor RFP tool to brief providers. If you have run studies through a site network, please write a review: published reviews are what give the next sponsor an evidence base.